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Background: Paclitaxel is highly effective in the treatment of many cancers in humans, but 
cannot be routinely used in dogs as currently formulated due to the exquisite sensitivity of this 
species to surfactant-solubilizing agents. CTI 52010 is a formulation of nanoparticulate paclitaxel 
consisting of drug and normal saline. Our objectives were to determine the maximally tolerated 
dose, dose-limiting toxicities, and pharmacokinetics of CTI 52010 administered intravenously 
to normal dogs.
Methods: Three normal adult hound dogs were evaluated by physical examination, complete 
blood count, chemistry profile, and urinalysis. Dogs were treated with staggered escalating 
dosages of CTI 52010 with a 28-day washout. All dogs were treated with a starting dosage 
of 40 mg/m2, and subsequent dosages were escalated at 50% (dog 1), 100% (dog 2), or 200% 
(dog 3) with each cycle, to a maximum of 240 mg/m2. Dogs were monitored by daily physical 
assessment and weekly laboratory evaluation. Standard criteria were used to grade adverse 
events. Plasma was collected at regular intervals to determine pharmacokinetics. Dogs were 
euthanized humanely, and necropsy was performed one week after the last treatment.
Results: The dose-limiting toxicity was grade 4 neutropenia and the maximum tolerated dosage 
was 120 mg/m2. Grade 1–2 gastrointestinal toxicity was noted at higher dosages. Upon post 
mortem evaluation, no evidence of organ (liver, kidney, spleen) toxicity was noted.
Conclusion: CTI 52010 was well tolerated when administered intravenously to normal dogs. 
A starting dosage for a Phase I/II trial in tumor-bearing dogs is 80 mg/m2.
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Introduction
Paclitaxel is an antimitotic taxane isolated from the western yew (Taxus brevifolia).1 
The mechanism of action of paclitaxel is to promote microtubules to form polymers 
which stabilize the resulting complex and inhibit microtubule disassembly. This results 
in inhibition of cell proliferation and induction of apoptosis.1,2 Paclitaxel has become 
an important component of cancer treatment, with significant antitumor activity against 
many types of malignancies, including ovarian, breast, head and neck, esophageal, and 
bladder carcinomas.3 Use of paclitaxel in dogs is limited due to an acute hypersensitivity 
reaction caused by the cosolvents required to make paclitaxel soluble. Standard forms 
of paclitaxel contain ethanol and polyethoxylated castor oil to solubilize it, and dogs are 
exquisitely sensitive to this formulation.3,4 Protein-bound paclitaxel, another common 
form, is a fine particle formulation coated with human serum albumin to increase its 
water solubility.5 However, using a foreign protein, such as human albumin in dogs, 
can also result in a hypersensitivity reaction.6
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Standard practice in human medicine for the   administration 
of paclitaxel includes the premedication of patients with 
drugs to block both the histamine 1 and histamine 2   receptors, 
in an attempt to counteract the effects of sensitivity to 
ethanol and polyethoxylated castor oil.3 This has led to the 
creation of several formulations of paclitaxel in recent years 
to eliminate the need for ethanol and polyethoxylated castor 
oil and therefore the need for premedications.7–10 CTI 52010 
is the simplest of these new formulations, consisting only of 
paclitaxel in a nanoparticulate form with saline. Production of 
CTI 52010 relies on supercritical carbon dioxide   processing. 
The nanoparticle size, 600–700 nm, allows the drug to exist as 
a stable suspension in saline without cosolvent, suspension-
enhancing agents, or other excipients.7,9
For many cancers in dogs, the current repertoire of 
  surgery, radiation, and chemotherapy has remained rela-
tively unchanged. Common cancers such as metastatic lung 
  cancer, lymphoma, prostate carcinoma, and osteosarcoma 
have not benefited from any major advance in the past 20 
years. New treatment options are necessary if we are to 
improve the quality of life for companion animals diag-
nosed with cancer. Paclitaxel therapy has been attempted in 
dogs with spontaneously occurring tumors, and preliminary 
efficacy was noted with breast and bone cancer.4 However, 
  toxicity was high; 64% of dogs had hypersensitivity reac-
tions despite heavy pretreatment with diphenhydramine 
and corticosteroids, and 12% had treatment-related deaths.4 
Yet, preliminary efficacy suggests that this group of drugs 
would expand our treatment options for dogs if a tolerable 
formulation existed.4 CTI 52010 has been well tolerated in 
preclinical rodent models and does not contain substances to 
which dogs should react.7 Therefore, CTI 52010 represents 
a novel chemotherapeutic agent that should be investigated 
as an anticancer agent in dogs.
Spontaneously occurring cancers in dogs are increas-
ingly recognized as a model for human cancer. Tumors in 
dogs share many clinical and molecular similarities to the 
corresponding cancer in people and provide the opportunity 
for an integrated comparative drug development pathway. 
Although rodent models are important for analyzing bio-
logic pathways in cancer formation and preliminary drug 
efficacy, pet dogs develop cancer naturally with an intact 
immune system and an environment shared with their human 
  counterparts. I  ncorporating dogs with spontaneously forming 
cancer into drug development will bridge the gap between 
rodent models and humans. Using dogs as a translational 
model can be used to confirm drug targets and provides 
proof of concept, in addition to providing information on best 
  treatment   schedules, pharmacokinetics, and drug toxicities 
prior to Phase I trials in people.11–13
The objectives of this study were to determine the maxi-
mally tolerated dose, dose-limiting toxicities, and plasma 
pharmacokinetics of intravenously delivered CTI 52010 in 
normal dogs to inform the starting dosage for a Phase II trial 
in tumor-bearing dogs.
Materials and methods
Drug production
CTI 52010 was produced by previously published methods.9 
Briefly, paclitaxel was recrystallized using the supercritical 
carbon dioxide process known as precipitation with com-
pressed antisolvent. Paclitaxel was dissolved in an organic 
solvent (acetone), which was sprayed as fine droplets into a 
chamber containing supercritical carbon dioxide. The result 
was removal of solvent from the solute into the supercritical 
carbon dioxide, causing the solute (drug) to precipitate as 
nanoparticles with reduced crystal size. These mild process-
ing conditions cause the drug to remain largely free of surface 
charge, with less tendency to agglomerate than fine particles 
prepared by grinding or ballistic methods. Furthermore, the 
result of this production method is a formulation of nano-
particulate paclitaxel consisting only of paclitaxel (without 
coating or matrix) and physiologic saline. This process was 
conducted in compliance with current good manufacturing 
practices.
Study design
Three normal adult hound dogs were obtained, housed, and 
handled according to the University of Missouri Animal 
Care and Use Committee approved protocol. Baseline 
evaluation consisted of physical examination, complete blood 
count, serum chemistry profile, and complete urinalysis. 
Serum chemistry profile evaluated renal values (blood urea 
nitrogen, creatinine), proteins (albumin, globulins), liver 
enzymes (alkaline phosphatase, alanine aminotransferase, 
gamma-glutamyl transpeptidase), total bilirubin, glucose, 
and electrolytes. Dogs were treated with staggered esca-
lating doses of CTI 52010 with a 28-day washout period. 
Following sedation and placement of a peripheral catheter 
for drug administration, a jugular catheter was placed for 
blood collection. All dogs were treated with an initial start-
ing dosage of 40 mg/m2 on day 0. CTI 52010 suspension 
5 mg/mL was delivered without dilution into a freely running 
line of saline over 30 minutes. Subsequent dose escalations 
for each treatment were scheduled as 50% (dog 1), 100% 
(dog 2), and 200% (dog 3) each cycle to a maximum dosage 
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of 240 mg/m2, meaning the final dose escalation in dog 3 was 
100% over the previous dose (Table 1). Dogs were scheduled 
for three total treatments, or until a dose-limiting toxicity was 
observed. Once a dose-limiting toxicity was documented, the 
next lowest dosage was considered the maximum tolerated 
dose for the purpose of identifying a starting dosage for dogs 
with spontaneously occurring tumors. This study design was 
developed to minimize the number of dogs and number of 
treatments required to reach our endpoints.
Monitoring schedule
All dogs were monitored on a daily basis by physical assess-
ment and weekly with chemistry profiles, and urinalysis. 
A complete blood count was performed biweekly following 
the first treatment cycle to determine nadirs of neutrophils 
and platelets and was assessed weekly thereafter. A coagula-
tion panel assessing prothrombin time and activated partial 
thromboplastin time was performed prior to each treatment 
and one week after each treatment. Additionally, a log book 
was kept for each dog, noting appetite, attitude, activity level, 
emesis, and any other health-related events. Hypersensitivity 
was evaluated by direct observation of each dog following 
treatment for clinical signs of an allergic reaction (facial 
swelling, flushing, urticaria, dyspnea, fever). Adverse events 
were graded according to Veterinary Co-operative Oncology 
Group adverse events criteria, version 1.14 A dose-limiting 
toxicity was defined as that which resulted in grade 4 hema-
tologic toxicity, grade 3 or higher toxicity of any other organ, 
or febrile grade 3 hematologic toxicity (Table 2). Dogs were 
humanely euthanized one week after the last treatment and 
underwent a complete post mortem evaluation.
Blood sampling
Whole blood (3 mL) was collected for pharmacokinetic analysis 
at nine specified time points, ie, at minutes 0, 15, 30, and 45, 
and then at hours 1, 2, 4, 8, and 24 following the start of drug 
infusion. Blood was collected into ethylenediamine tetraacetic 
acid tubes, and samples were centrifuged within 20 minutes 
of sample collection. Plasma was collected immediately and 
frozen at −20°C until assayed. Samples for each treatment group 
were assayed concurrently within three months of collection.
Pharmacokinetic data analysis
Actual doses were calculated based on body surface area of 
the animals on treatment day. Samples were collected at time 
points listed above. A simplified high performance liquid 
chromatography (HPLC) separation was used for analysis; 
samples were spiked with docetaxel as an internal standard 
and extracted, then analyzed by HPLC. HPLC separation for 
paclitaxel was optimized using 5 micron L43 packing in a 
6 mm × 250 mm column. Starting conditions were a flow rate 
of 1.5 mL/minute, column temperature of 30°C, and a mobile 
phase consisting of acetonitrile and water in a ratio of 9:11. 
The elution was isocratic and the run time was 15 minutes. 
Initial runs contained only paclitaxel and docetaxel standards, 
and operating parameters were adjusted to achieve full separa-
tion of paclitaxel from the internal standard docetaxel. After 
reproducible conditions were established and equipment 
calibrated for good laboratory practice compliance, spiked 
samples of canine plasma were analyzed to determine recov-
ery efficiency and a calibration curve was constructed. One 
milliliter samples of blank canine plasma were spiked with 
five levels of paclitaxel ranging from 2 ng to 100 ng and with 
the internal standard, docetaxel. Samples were extracted with 
ethyl acetate, separated by centrifugation, dried by evapora-
tion, and reconstituted in acetonitrile/water for injection into 
the HPLC. Limit of detection, limit of quantification, percent 
recovery, slope, intercept, and correlation coefficient were 
determined and a standard operating procedure was written 
for the protocol. The standard curves were used to calculate 
plasma concentration levels of treated animals (Figure 1).
Blood samples for pharmacokinetic analysis were drawn 
at the aforementioned time points. Plasma was collected and 
frozen for delivery to CritiTech for analysis. The samples 
were spiked with docetaxel as internal standard and extracted 
as described above, then analyzed by the HPLC method on a 
Hitachi L7000 series HPLC with L7200 autosampler, L7400 
ultraviolet detector, and operated with TotalChrom software.
Paclitaxel concentrations were determined by comparison 
with the standard curve and the blank sample run with each 
batch analyzed. Multiple dilutions of samples were as needed 
to ensure that paclitaxel levels fell within the range of the 
standard curve. Maximum plasma concentration, plasma 
Table 1 Dosing schedule of CTI 52010
Day Dog 1 Dog 2 Dog 3
% increase Dosage (mg/m2) % increase Dosage (mg/m2) % increase Dosage (mg/m2)
0 0 40 0 40 0 40
28 50 60 100 80 200 120
56 50 90 100 160 100 240
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half-life (t1/20–24), volume of distribution, mean residence 
time, and area under the curve were calculated for each test 
animal using PK Solutions software (PK Solutions Pharma-
cokinetics Data Analysis version 2.0 from Summit Research 
Services Montrose, CO).
Post mortem examination
One week following the last treatment, all dogs were 
humanely euthanized with administration of intravenous 
pentobarbital and gross postmortem examination with his-
topathology of all organs performed. Additionally, tissue 
samples were collected during post mortem examination for 
extraction of CTI 52010.
Tissue homogenization and extraction
Liver, spleen, and kidney tissue samples (0.5 g) were 
  collected from each dog during post mortem examination 
and were placed into separate 15 mL polypropylene conical 
tubes with 1 mL HPLC water. The samples were then placed 
in a −35°C acetone/water/dry ice bath. Using a Misonix 
sonifier with a 3/16 inch tip, at power level five, the tissues 
were homogenized by placing the tip on tissue, and blend-
ing for 35 seconds, resulting in liquid homogenate that 
was transferred to polyethylene microcentrifuge tubes in 
400 µL aliquots. Twenty microliters of internal standard 
was added to each sample, samples were vortexed, and 1 mL 
of methyl-t-butyl ether was added. The samples were then 
shaken by hand for 10 minutes, followed by 10 minutes 
of centrifugation. Samples were placed in an acetone/dry 
ice bath at −50°C for two minutes, and the methyl-t-butyl 
ether layer was decanted into polyethylene microcentrifuge 
tubes. A CentriVap was used for 15 minutes to dry samples, 
and samples were then reconstituted and transferred to 
autosample vials with microinserts. Aliquots of 100 µL were 
used for HPLC.
Results
Three adult hound dogs were obtained from a certified dealer 
and determined healthy based on physical examination. 
Complete blood counts, coagulation panels, serum chemistry 
profiles, and urinalyses were within normal limits in all three 
dogs at baseline (data not shown).
Side effects are summarized in Table 3. No evidence of 
hypersensitivity was noted in any dog at any dosage. No 
gastrointestinal toxicity was noted in any dog at dosages up to 
120 mg/m2, other than Grade 1 nausea in one dog treated with 
90 mg/m2. Grade 1 and 2 gastrointestinal toxicity and grade 
Table 2 Veterinary Co-operative Oncology group criteria for adverse events following chemotherapy (version 1)
Adverse event Grade 1  
(mild)
Grade 2  
(moderate)
Grade 3  
(severe)
Grade 4  
(life-threatening)
Grade 5 
(death)
Nausea Loss of appetite  
with no alteration  
in eating habits
Salivation, lick smacking  
,12 hours
Salivation, lick smacking  
.12–24 hours
Salivation, lick  
smacking .24 hours
N/A
Vomiting ,3 episodes in  
24 hours
3–5 episodes in 24 hours; ,3  
episodes per day for 2–5 days;  
parenteral fluids indicated for  
,24 hours
.5 episodes in 24 hours  
or vomiting for .4 days  
Parenteral fluids indicated  
for .24 hours
Life-threatening  
(hemodynamic  
collapse)
Death
Diarrhea Increase of .2  
stools per day  
over baseline
Increase of 2–6 stools per  
day over baseline; parenteral  
fluids indicated ,24 hours
Increase of .6 stools  
per day over baseline,  
incontinence, parenteral  
fluids .24 hours
Life-threatening  
(hemodynamic  
collapse)
Death
Neutropenia 1500/µL, lower  
limit of normal
1000–1499/µL 500–999/µL ,500µL N/A
Thrombocytopenia 100,000/µL, lower  
limit of normal
50,000–99,000/µL 25,000–49,000/µL ,25,000/µL N/A
Note: Copyright© 2004. John Wiley and Sons. reproduced with permission from Veterinary Cooperative Oncology group. Veterinary Co-operative oncology group – common 
criteria for adverse events (VCOg–CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol. 2004;2:194–213.14
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Figure 1 Paclitaxel standard curve used to calculate plasma concentration levels 
of treated animals.
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4 myelotoxicity were noted at 160 mg/m2 and 240 mg/m2. 
When treated with 80–120 mg/m2, grades 1 and 2 myelo-
toxicity occurred. A mild to moderate thrombocytopenia 
occurred in most dogs 10–14 days following treatment. 
One dog experienced an elevation in both prothrombin time 
and partial thromboplastin time one week following treat-
ment with 40 mg/m2 and 120 mg/m2doses. The coagulation 
abnormalities resolved within three weeks, prior to the next 
scheduled treatment. The dose-limiting toxicity was neutro-
penia at a nadir of seven days, and the maximum tolerated 
dose was determined to be 120 mg/m2.
Dogs were humanely euthanized using pentobarbital 
administered intravenously. Upon post mortem examination 
of all dogs, no evidence of toxicity was noted in the liver, 
  kidney, or spleen (Figures 2 and 3). Drug accumulation was 
noted in the liver and spleen, but not the kidney (Figure 4). 
Drug concentrations in the liver and spleen were propor-
tional to dose. Liver tissue concentrations of CTI 52010 
were 94.49 µg/g, 54.89 µg/g, and 17.58 µg/g in dogs treated 
with the highest to lowest doses, respectively. Similarly, tis-
sue concentrations of drug in the spleen were 33.34 µg/g, 
19.86 µg/g, and 11.63 µg/g, respectively. Concentration 
of drug in the kidneys was similar in all three dogs. Evi-
dence of mild gastritis was seen in the two dogs treated at 
higher dosages. In one dog, this gastritis was described as 
lymphocytic-plasmacytic.
Pharmacokinetic data
The values of pharmacokinetic parameters for intravenously 
administered CTI 52010 at six dose levels ranging from 60 to 
240 mg/m2 are summarized in Table 4. It was not possible to 
generate pharmacokinetic data at the 40 mg/m2 dosage because 
concentrations in all samples were below the limit of detec-
tion. The area under the curve ranged from 891 ng-hour/mL 
to 1316 ng-hour/mL. The apparent elimination t1/20–24 ranged 
from 9.9 to 203.4 hours, with a median of 39.5 hours. The time 
Table 3 Summary of side effects seen with increasing doses of CTI 52010 using the Veterinary Co-operative Oncology group 
(VCOg) – common criteria for adverse events version 1 criteria following chemotherapy (see also Table 2). Each cell represents a 
single adverse event in one dog
Side effect Vomiting  
(Grade)
Nausea  
(Grade)
Neutropenia 
(Grade)
Thrombocytopenia 
(Grade)
Dose (mg/m2)
40 grade 1
60
80 grade 2 grade 1
90 grade 1 grade 1 grade 1
120 grade 1
160 grade 2 grade 4 (DLT) grade 3
240 grade 1 grade 4 (DLT) grade 1
Note:  Copyright©  2004.  John  Wiley  and  Sons.  reproduced  with  permission  from  Veterinary  Cooperative  Oncology  group.  Veterinary  Co-operative  oncology 
group – common criteria for adverse events (VCOg–CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol. 
2004;2:194–213.14
Abbreviation: DLT, dose-limiting toxicity.
Figure 2 Histopathology of the liver in a treated dog, showing no evidence of 
change compared with normal liver.
Figure 3 Histopathology of the spleen in a treated dog, showing no evidence of change 
compared with normal spleen. This picture also shows occasional macrophages that 
contain golden-brown pigment granules consistent with hemosiderin.
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to peak drug concentration was 0.5 hours, and the volume of 
distribution ranged from 1691 L to 2749 L (median 2251 L). 
The maximum plasma concentration ranged from 319 ng/mL 
to 4531 ng/mL (median 2020 ng/mL). The mean residence 
time was 8.8–258 (median 47.4) hours.
Discussion
The taxanes represent an important class of anticancer agents 
because of their broad spectrum of activity. Paclitaxel has 
limited solubility in water, and is most often formulated in 
a mixture with 50% ethanol and 50% polyethoxylated cas-
tor oil. Although effective at dissolving paclitaxel, these are 
thought to be the cause of acute hypersensitivity reactions 
observed during and following administration. Standard 
practice calls for premedication of patients with diphenhy-
dramine, cimetidine or ranitidine, and dexamethasone to 
counteract the adverse effect of the solvents. Accordingly, 
several formulations of paclitaxel are being developed to 
eliminate the need for solvents. CTI 52010 is the simplest 
of these new formulations, consisting solely of drug and 
saline. The nanoparticle size and production method allow 
the nanoparticulate paclitaxel to exist stably without solvent, 
cosolvent, suspension-enhancing agents, or a stabilizing 
matrix.
Standard formulations of paclitaxel are not recommended 
for use in dogs due to their exquisite sensitivity to polyethoxy-
lated castor oil; in 25 tumor-bearing dogs, 64% had signs 
of an allergic reaction including hives, head shaking, skin 
flushing, and pruritus, despite heavy premedication using 
diphenhydramine, cimetidine, and dexamethasone. Other 
side effects noted with paclitaxel are similar to those noted 
in this study, including myelosuppression, vomiting, and 
  diarrhea.4 These side effects are expected and for the most 
part easily treatable in canine cancer patients. Albumin-bound 
formulations of paclitaxel are also not advised for use in 
dogs, because an immediate or delayed hypersensitivity 
reaction occurs in healthy dogs when human albumin is 
administered.6
The aim of this study was to determine the maximum tol-
erated dose, toxicities, and pharmacokinetics of CTI 52010, 
a nanoparticulate paclitaxel without solubilizing agents, in 
normal dogs. The maximum tolerated dose was 120 mg/m2, 
and the dose-limiting toxicity was neutropenia.   Gastrointestinal 
toxicity was mild and only seen in those dogs receiving high 
doses of drug. Because gastrointestinal toxicity is a major con-
cern for pet owners pursuing chemotherapy for their dogs, this 
limited toxicity makes CTI 52010 an attractive chemotherapy 
agent. Biochemistry panel, urinalyses, coagulation parameters, 
prothrombin time, and partial thromboplastin time were evalu-
ated in each dog prior to treatment (baseline) and one week 
after treatment. No clinically significant changes were seen in 
the coagulation panels in any dog, nor were significant changes 
noted in the biochemistry panel or urinalyses. On post mortem 
examination, no organ toxicity was noted. Hepatic detoxifying 
enzymes were not measured in this study. However, this could 
be considered in future studies as a possible explanation for 
pharmacokinetic variability. The intravenous administration 
of a nanoparticulate formulation of paclitaxel did not result 
in any evidence of a thrombotic event in any dog.
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Figure 4 Tissue concentrations of CTI 52010. Accumulation of CTI 52010 was 
determined post mortem in the liver, kidney, and spleen of all three dogs using high-
pressure liquid chromatography following tissue homogenization and extraction.
Table 4 Pharmacokinetic parameters for CTI 52010 determined after intravenous administration
Parameter Dosage 60 mg/m2 80 mg/m2 90 mg/m2 120 mg/m2 160 mg/m2 240 mg/m2
AUC  
(ng-hr/mL)
891 577 509 285 1304 1316
t1/20–24 203.4 116.3 42.7 9.9 37.2 24.7
Vd (L) 2288 2522 2749 2289 1691 2251
Cmax  
(ng/mL)
3545 327 N/A 319 4531 2020
MrT  
(area in hours)
258 161 57 8.8 37.8 29.8
Abbreviations: AUC, area under the curve; MrT, mean residence time; t1/2, elimination half-life; Cmax, peak plasma concentration.
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Furthermore, no evidence of hypersensitivity was noted 
in any dog, at any dosage, and no pretreatment was used in 
this study. Since CTI 52010 is a formulation of paclitaxel 
consisting solely of paclitaxel and saline, it does not cause 
hypersensitivity, and a new class of chemotherapeutics can 
be added to the current repertoire of drugs commonly used 
to treat canine cancer.
The apparent t1/20–24 ranged from 9.9 hours to 203.4 hours. 
This long and variable half-life is possibly due to drug accu-
mulation in the liver and spleen. Previous studies using the 
standard formulation of paclitaxel solubilized with poly-
ethoxylated castor oil revealed a terminal t1/2 of 1.9 hours.15 
The prolonged t1/2 in CTI 52010 can be exploited for 
therapeutic gain in tumors of the liver and spleen, providing 
a potential therapeutic advantage over standard paclitaxel 
formulations. We chose a 28-day washout period between 
treatments based on the metabolism and clearance of other 
chemotherapeutic agents, and without prior knowledge of the 
extended half-life. However, despite the possibility of drug 
accumulation contributing to toxicity, this study design did 
allow us to achieve our goals. It is possible that our starting 
dosage for a Phase II trial in tumor-bearing dogs will be low 
if drug accumulation contributed to toxicity, because adverse 
events would have been detected at lower dosages. Therefore, 
a rapid dose escalation scheme is appropriate for a Phase II 
trial in tumor-bearing dogs.
There was minimal accumulation of CTI 52010 in the 
kidneys, which is in contrast with other nanoparticulate 
formulations of paclitaxel studies in mice. However, many 
nanoparticulate formulations use a polymeric coating such 
as gelatin.15 CTI 52010 is produced using precipitation with 
compressed antisolvents, and polymeric coatings are not 
needed. Due to the production methods used, CTI 52010 
contains only paclitaxel in nanoparticulate form, and avoids 
the toxicities associated with gelatin or other matrices used 
in other nanoparticle production methods.
Standard formulations of paclitaxel result in low levels 
of uptake in the liver and spleen, while liposomal paclitaxel 
accumulates in the lungs.16 In contrast, accumulation of 
CTI 52010 was noted in the spleen and liver of all dogs in this 
study, with concentrations highest in the dog administered the 
highest cumulative dosage. Drug accumulation in these two 
organs is likely due to nanoparticle uptake by macrophages 
in the reticuloendothelial system, a phenomenon that may be 
exploited for therapeutic gain against certain tumor types. 
Histiocytic sarcomas, for example, are a common cancer 
type originating from macrophages and dendritic cells in 
both the liver and spleen. There are currently no effective 
chemotherapeutic agents for liver cancer or histiocytic 
cancers, and the accumulation of CTI 52010 in the liver and 
spleen makes it an attractive agent for the treatment of these 
cancer types. Additionally, taxanes have shown preliminary 
efficacy in breast and bone cancer in dogs. Two dogs with 
metastatic mammary carcinoma and two dogs with metastatic 
osteosarcoma treated with standard paclitaxel experienced 
a partial remission. All of these dogs were resistant to other 
chemotherapeutics.4 These two types of cancer are common 
canine malignancies, yet no recent research has provided a 
change in the current standard of care. There are many can-
cers for which CTI 52010 has the potential to be used to treat 
tumor-bearing dogs effectively, thus improving their quality 
of life. With the maximum tolerated dose and dose-limiting 
toxicity determined in this study, a Phase II trial can be initi-
ated for dogs with spontaneously occurring cancer to obtain 
more pharmacokinetic and antitumor efficacy data.
Dogs also serve as a model for people and can guide 
the development of novel chemotherapy and biological or 
targeted treatments for cancer in both species.11–13 Currently, 
a Phase I study of nanoparticulate paclitaxel administered 
via the intraperitoneal route to human cancer patients is 
underway. The pharmacokinetic and toxicity data provided 
by our study can improve the efficiency of the drug devel-
opment pathway, offering a new route of administration of 
  nanoparticulate paclitaxel, thus further benefiting human can-
cer patients. Furthermore, using the novel system precipitation 
with compressed antisolvent to produce CTI 52010, stable 
suspensions of paclitaxel nanoparticles in physiologic saline 
are formed and easily injected as a suspension. This prepara-
tion is ideal, because it is devoid of polyethoxylated castor oil 
and its undesirable side effects, and allows controlled particle 
size distribution and consistent product quality.7
In conclusion, the study reported here demonstrates the 
maximum tolerated dose, dose-limiting toxicity, and pharma-
cokinetics of CTI 52010 in normal dogs. The results of this 
study indicate that a Phase II efficacy trial in tumor bearing 
dogs is feasible, and provide a starting point for dosing in 
future trials.
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